Your browser doesn't support javascript.
Impact of comorbidity on patients with COVID-19 in India: A nationwide analysis.
Singh, Priya; Bhaskar, Yogendra; Verma, Pulkit; Rana, Shweta; Goel, Prabudh; Kumar, Sujeet; Gouda, Krushna Chandra; Singh, Harpreet.
  • Singh P; Division of Biomedical Informatics, Indian Council of Medical Research, New Delhi, India.
  • Bhaskar Y; Division of Biomedical Informatics, Indian Council of Medical Research, New Delhi, India.
  • Verma P; Division of Biomedical Informatics, Indian Council of Medical Research, New Delhi, India.
  • Rana S; Division of Biomedical Informatics, Indian Council of Medical Research, New Delhi, India.
  • Goel P; Department of Paediatric Surgery, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
  • Kumar S; Centre for Proteomics and Drug Discovery, Amity University Maharashtra, Mumbai, India.
  • Gouda KC; Earth and Engineering Sciences Division, CSIR Fourth Paradigm Institute, Bangalore, India.
  • Singh H; Division of Biomedical Informatics, Indian Council of Medical Research, New Delhi, India.
Front Public Health ; 10: 1027312, 2022.
Article in English | MEDLINE | ID: covidwho-2311001
ABSTRACT

Background:

The emergence of coronavirus disease (COVID-19) as a global pandemic has resulted in the loss of many lives and a significant decline in global economic losses. Thus, for a large country like India, there is a need to comprehend the dynamics of COVID-19 in a clustered way.

Objective:

To evaluate the clinical characteristics of patients with COVID-19 according to age, gender, and preexisting comorbidity. Patients with COVID-19 were categorized according to comorbidity, and the data over a 2-year period (1 January 2020 to 31 January 2022) were considered to analyze the impact of comorbidity on severe COVID-19 outcomes.

Methods:

For different age/gender groups, the distribution of COVID-19 positive, hospitalized, and mortality cases was estimated. The impact of comorbidity was assessed by computing incidence rate (IR), odds ratio (OR), and proportion analysis.

Results:

The results indicated that COVID-19 caused an exponential growth in mortality. In patients over the age of 50, the mortality rate was found to be very high, ~80%. Moreover, based on the estimation of OR, it can be inferred that age and various preexisting comorbidities were found to be predictors of severe COVID-19 outcomes. The strongest risk factors for COVID-19 mortality were preexisting comorbidities like diabetes (OR 2.39; 95% confidence interval (CI) 2.31-2.47; p < 0.0001), hypertension (OR 2.31; 95% CI 2.23-2.39; p < 0.0001), and heart disease (OR 2.19; 95% CI 2.08-2.30; p < 0.0001). The proportion of fatal cases among patients positive for COVID-19 increased with the number of comorbidities.

Conclusion:

This study concluded that elderly patients with preexisting comorbidities were at an increased risk of COVID-19 mortality. Patients in the elderly age group with underlying medical conditions are recommended for preventive medical care or medical resources and vaccination against COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Aged / Humans Language: English Journal: Front Public Health Year: 2022 Document Type: Article Affiliation country: Fpubh.2022.1027312

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Aged / Humans Language: English Journal: Front Public Health Year: 2022 Document Type: Article Affiliation country: Fpubh.2022.1027312